Addiction Therapeutics - Global Strategic Business Report

The global market for Addiction Therapeutics was estimated at US$25.2 Billion in 2024 and is projected to reach US$36.0 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Addiction Therapeutics market.

Global Addiction Therapeutics Market - Key Trends & Drivers Summarized

Why Are Addiction Therapeutics Gaining Strategic Significance Across Public Health, Behavioral Medicine, and Pharmaceutical Innovation?

Addiction therapeutics are becoming a global health imperative as the burden of substance use disorders (SUDs) including opioid, alcohol, nicotine, and stimulant dependencies continues to rise. With addiction now widely recognized as a chronic neurobehavioral condition rather than a moral failing, there is growing acceptance of pharmacological intervention as a core component of comprehensive treatment strategies. Therapeutics aimed at managing cravings, withdrawal symptoms, and relapse prevention are gaining clinical traction across rehabilitation, psychiatric, and primary care settings.

The opioid crisis in North America, alcohol dependence in Europe, and increasing stimulant abuse in Asia-Pacific have prompted governments to prioritize addiction treatment under national healthcare agendas. Broader social drivers such as rising mental health challenges, economic insecurity, and pandemic-induced isolation are further amplifying the urgency of accessible, evidence-based treatment solutions. As demand escalates, addiction therapeutics are being integrated into public insurance schemes, employee assistance programs, and court-mandated treatment initiatives.

Pharmaceutical innovation in addiction therapy is also gaining momentum, with efforts focused on developing drugs that modulate neuroreceptors (e.g., opioid, dopamine, GABA), block reward pathways, and manage dual diagnoses involving depression or anxiety. These treatments are being designed not only to reduce substance dependence but also to restore neurological balance and behavioral function, highlighting their centrality in recovery-oriented healthcare models.

How Are Novel Mechanisms, Digital Integration, and Policy Reforms Driving the Evolution of Addiction Therapeutics?

The addiction therapeutics pipeline is expanding through advances in neuropharmacology, offering more targeted and tolerable interventions. Long-acting injectables, depot formulations, and implantable devices are addressing adherence challenges and reducing misuse potential. Partial agonists, antagonists, and modulators of reward circuitry are under clinical development for a wide spectrum of addictions ranging from alcohol and opioids to emerging behavioral addictions like gambling and gaming.

Integration of digital tools including mobile health apps, virtual behavioral support, and AI-driven adherence monitoring is enhancing the effectiveness of pharmacotherapy. These tools facilitate medication reminders, craving tracking, and virtual therapy support, offering a hybrid care model that blends pharmacological and psychosocial treatment. Digital therapeutics (DTx) are increasingly paired with prescription drugs, particularly in markets with strong telehealth adoption and payer support for value-based care models.

Policy reforms are removing longstanding access barriers to addiction medications. Expansion of prescribing rights to nurse practitioners, reduction of mandatory counseling requirements for certain medications, and streamlining of reimbursement for combination therapies are catalyzing uptake. Additionally, regulatory bodies are accelerating approvals for breakthrough therapies under fast-track or priority review programs, recognizing the urgency of the addiction crisis. These reforms are reshaping the treatment landscape by promoting early intervention, reducing stigma, and prioritizing harm reduction over punitive approaches.

Which Patient Populations, Treatment Modalities, and Regional Markets Are Driving the Growth of Addiction Therapeutics?

Key patient groups include individuals with opioid use disorder (OUD), which remains the primary focus of current therapeutics, particularly in the U.S. and Canada. Alcohol use disorder (AUD) accounts for a substantial share of treatment demand globally, especially in Europe and parts of Latin America. Tobacco cessation products, including both prescription medications and over-the-counter options, also represent a high-volume, broad-access segment across all geographies.

Treatment modalities range from detoxification support and maintenance therapy to relapse prevention and dual-diagnosis management. Common pharmacological agents include methadone, buprenorphine, naltrexone, acamprosate, disulfiram, and varenicline, each aligned with specific substance dependencies and patient profiles. Emerging modalities include cannabinoid-based therapies, psychedelic-assisted interventions, and anti-craving agents with novel neurological targets.

North America leads the addiction therapeutics market due to robust healthcare funding, ongoing public health crises, and advanced clinical infrastructure. Europe follows closely, supported by universal healthcare systems and progressive drug policy environments. Asia-Pacific is showing increasing adoption, particularly in urban centers grappling with alcohol and stimulant abuse. However, stigma, limited access to specialized providers, and variable insurance coverage remain barriers in emerging markets.

What Strategic Role Will Addiction Therapeutics Play in Shaping Future Health Systems, Societal Resilience, and Neuropsychiatric Care Innovation?

Addiction therapeutics are poised to play a strategic role in transitioning healthcare systems toward integrated, outcomes-focused, and socially responsive models of care. As the link between addiction, mental health, and social determinants becomes more evident, pharmacological interventions are being embedded into broader ecosystems of recovery spanning housing, employment, peer support, and justice reform.

Pharmaceutical and biotech players are leveraging this momentum to explore adjacent therapeutic areas such as post-traumatic stress disorder, chronic pain without opioids, and neuroregeneration expanding the innovation horizon beyond conventional addiction treatment. Collaborative funding models involving public health agencies, insurers, and tech-enabled care providers are enabling a.

With societal attitudes shifting from criminalization to compassion and science-driven care, could addiction therapeutics become the cornerstone of a global transformation in how we treat, perceive, and ultimately prevent substance-related and behavioral health disorders?

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Alcohol Addiction Therapeutics segment, which is expected to reach US$18.2 Billion by 2030 with a CAGR of a 4.9%. The Tobacco Addiction Therapeutics segment is also set to grow at 7.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $6.9 Billion in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $7.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Addiction Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Addiction Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Addiction Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Alkermes plc, Alkaloid AD Skopje, Biovail Corporation, Camurus AB, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Addiction Therapeutics market report include:

• Alkermes plc
• Alkaloid AD Skopje
• Biovail Corporation
• Camurus AB
• Durect Corporation
• Indivior PLC
• Jazz Pharmaceuticals plc
• Lundbeck A/S
• Mallinckrodt Pharmaceuticals
• MediciNova, Inc.
• Novartis AG
• Otsuka Holdings Co., Ltd.
• Pfizer Inc.
• Reckitt Benckiser Group plc
• Retrophin, Inc.
• Shionogi & Co., Ltd.
• Sunovion Pharmaceuticals
• Teva Pharmaceutical Industries
• Titan Pharmaceuticals, Inc.
• Zogenix, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.